Mounjaro Side Effects: What to Expect & How to Manage Them
Summary: The most common side effects of Mounjaro are gastrointestinal — nausea, diarrhoea, vomiting, constipation, and dyspepsia. These are most pronounced during dose escalation and improve significantly by weeks 6–10 for most patients. In the SURMOUNT-1 trial, only 4.3% of participants at the 15 mg dose discontinued treatment due to gastrointestinal side effects, meaning more than 95% continued.
Overview
Like all medicines, Mounjaro (tirzepatide) can cause side effects. The majority are mild to moderate, are concentrated during the early weeks of treatment and dose escalation, and improve substantially as the body adapts. Serious side effects are uncommon but important to recognise.
Understanding what to expect — and how to manage it — significantly improves tolerability and reduces unnecessary discontinuation. Many patients who stop treatment early due to nausea or diarrhoea could have continued successfully with simple dietary adjustments and, where appropriate, a slower dose escalation.
This guide covers the full side-effect profile of tirzepatide as described in the MHRA-approved Summary of Product Characteristics (SmPC) and the SURMOUNT clinical trial programme. For a full explanation of how Mounjaro works, see: How Does Mounjaro Work? The Science Behind Tirzepatide.
Common gastrointestinal side effects
Gastrointestinal (GI) effects are the most frequently reported side effects of tirzepatide and are classified as very common (affecting ≥1 in 10 patients) in the SmPC. They arise because tirzepatide slows gastric emptying and activates gut hormone receptors throughout the digestive tract.
| Side effect | Frequency (SURMOUNT-1, 15 mg) | Typical onset |
|---|---|---|
| Nausea | Very common (≥1/10) | First 1–4 weeks; peaks at dose escalation |
| Diarrhoea | Very common (≥1/10) | First 1–4 weeks; improves with time |
| Vomiting | Very common (≥1/10) | Often accompanies nausea; usually brief |
| Constipation | Very common (≥1/10) | Can occur alongside or alternating with diarrhoea |
| Dyspepsia / GERD | Very common (≥1/10) | Worsened by high-fat meals and lying down after eating |
| Abdominal pain | Common (1/10 to 1/100) | Usually mild; can accompany other GI effects |
| Bloating / flatulence | Common (1/10 to 1/100) | Often related to dietary changes and slowed motility |
Other common side effects
In addition to gastrointestinal effects, the following are reported as common (≥1 in 100 patients) in clinical trial data and post-marketing experience:
- Fatigue: Often most noticeable in the first few weeks; usually transient.
- Appetite reduction: This is an intended pharmacological effect rather than an adverse event, but some patients find it more marked than expected.
- Headache: Reported particularly during the initial weeks of treatment; typically mild.
- Dizziness: Usually mild and transient; may be related to reduced calorie intake or dehydration.
- Injection site reactions: Redness, bruising, or minor discomfort at the injection site. Rotating injection sites each week reduces this.
- Increased heart rate: A small increase in resting heart rate (typically 2–4 beats per minute) has been observed; usually clinically insignificant but should be monitored in patients with pre-existing cardiac conditions.
How to manage side effects
The following practical measures significantly improve tolerability during dose escalation. Most patients find that side effects are manageable with straightforward dietary and behavioural adjustments.
- Eat smaller meals more frequently — large meals are harder to tolerate when gastric emptying is slowed
- Eat slowly and chew food thoroughly before swallowing
- Avoid high-fat, fried, and heavily spiced foods — these worsen nausea and dyspepsia
- Avoid very sweet or sugary foods, which can trigger or worsen nausea
- Stay well hydrated: aim for 1.5–2 litres of water daily, sipping steadily rather than drinking large amounts at once
- Choose bland foods (plain rice, toast, boiled potatoes, crackers) when nausea is at its peak
- Do not lie down for at least 2 hours after eating — this reduces reflux and nausea
- Inject at the same time each week (morning or evening — your choice) to maintain a consistent pharmacological level
- If side effects are severe, speak to your prescriber about slowing the dose escalation: remaining at a lower dose for an extra 4 weeks before increasing is a safe and commonly used strategy
- Maintain adequate protein intake (at least 1.2 g per kilogram of body weight daily) to support lean mass preservation and energy levels
Dose escalation flexibility: The standard 4-weekly escalation schedule is not mandatory. If you are experiencing side effects that are significantly affecting your quality of life, your prescriber can recommend remaining at your current dose for an additional 4 weeks before moving to the next step. Do not escalate ahead of schedule, and always discuss changes with your prescriber.
How long do side effects last?
For most patients, gastrointestinal side effects are most pronounced during the first 4–8 weeks and at each dose escalation step. They typically diminish substantially by weeks 6–10 as the body adapts.
| Treatment phase | Dose | Typical side-effect pattern |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Mild nausea, possible appetite reduction. Most patients tolerate this phase well. The low starting dose minimises early-onset side effects. |
| Weeks 5–8 | 5 mg | First dose increase; nausea and diarrhoea may become more noticeable. Usually manageable with dietary adjustments. Peak of early side effects for many patients. |
| Weeks 9–16 | 7.5–10 mg | Side effects often diminish as tolerance builds. Some patients experience a brief re-emergence of mild nausea at each escalation step, typically lasting 1–2 weeks. |
| Week 21 onwards | 15 mg (maintenance) | Most patients at maintenance dose report markedly reduced GI side effects compared to the escalation phase. Tolerability generally improves further over subsequent months. |
Uncommon and serious side effects
The following side effects are uncommon (affecting fewer than 1 in 100 patients) but are clinically important. Patients should be aware of them and know when to seek prompt medical advice.
Pancreatitis
Acute pancreatitis has been reported with tirzepatide and other GLP-1 receptor agonists. The presenting symptom is severe abdominal pain, typically in the upper central or left upper abdomen, which may radiate to the back and is often accompanied by nausea and vomiting. If this pattern of pain occurs, stop taking Mounjaro and seek urgent medical attention. Mounjaro is contraindicated in patients with a history of pancreatitis.
Gallbladder disease
Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported in patients taking tirzepatide, consistent with effects seen with other agents causing rapid weight loss. Symptoms include pain in the right upper abdomen, particularly after fatty meals. Persistent right upper abdominal pain should be investigated by a doctor.
Hypoglycaemia
In patients without diabetes, tirzepatide alone does not cause hypoglycaemia because its insulin-stimulating effect is glucose-dependent (it only works when blood glucose is elevated). However, in patients taking concurrent insulin or sulphonylurea medications, the risk of low blood sugar is increased. Symptoms include sweating, trembling, dizziness, confusion, and palpitations. Patients on these combinations should have their diabetes medication reviewed by their prescriber.
Increased resting heart rate
A small, typically transient increase in resting heart rate has been observed with tirzepatide. In clinical trials the mean increase was approximately 2–4 beats per minute. For most patients this is of no clinical significance, but patients with pre-existing cardiac conditions should be monitored.
Acute kidney injury
Severe gastrointestinal side effects leading to dehydration can rarely precipitate acute kidney injury. Maintaining adequate fluid intake is therefore clinically important, not merely a comfort measure. Contact your GP if you are unable to keep fluids down for more than 24 hours.
Red flags: when to seek urgent help
Stop Mounjaro and seek urgent medical attention (call 999 or go to A&E) if you experience any of the following:
- Severe, persistent abdominal pain radiating to the back (possible pancreatitis)
- Signs of a severe allergic reaction: facial, lip, tongue, or throat swelling; difficulty breathing or swallowing; rapid heartbeat; dizziness (possible anaphylaxis)
- Symptoms of hypoglycaemia in a patient also taking insulin or a sulphonylurea: sweating, trembling, confusion, loss of consciousness
- Sudden changes in vision (possible diabetic retinopathy progression)
- Persistent right upper abdominal pain, especially after fatty meals (possible gallbladder disease)
- Inability to keep fluids down for more than 24 hours (risk of dehydration and acute kidney injury)
For non-urgent side effects that are not resolving or are significantly affecting your daily life, contact your prescriber or call NHS 111.
Hair loss and Mounjaro
Hair thinning is reported by some patients during Mounjaro treatment. It is important to understand the mechanism, as it is frequently misattributed to tirzepatide itself.
The correct clinical explanation is telogen effluvium: a well-established, temporary form of hair shedding triggered by significant physiological stress on the body, including rapid weight loss. When the body loses weight quickly, the hair growth cycle is disrupted; a larger proportion of follicles simultaneously enter the resting (telogen) phase and shed. This is not a direct pharmacological effect of tirzepatide.
2–3
Months after rapid weight loss onset when hair shedding typically begins
3–6
Months for hair to typically recover once weight loss stabilises
To minimise the risk and severity of telogen effluvium during treatment:
- Maintain a daily protein intake of at least 1.2 g per kilogram of body weight — protein is the primary structural component of hair
- Ensure adequate intake of micronutrients including iron, zinc, biotin, and vitamin D — consider a multivitamin supplement during active weight loss
- Avoid crash dieting or extreme calorie restriction alongside Mounjaro — a moderate deficit is more sustainable and less physiologically stressful
- Be reassured that hair typically regrows once weight loss stabilises — this is a temporary disruption, not permanent hair loss
Who should not take Mounjaro?
Mounjaro is contraindicated or requires particular caution in the following groups. A prescriber will assess these factors before issuing a prescription.
- Pregnancy: Mounjaro must not be used during pregnancy. Women of childbearing age should use effective contraception during treatment. Weight loss itself can affect the efficacy of hormonal contraception; discuss with your prescriber.
- Breastfeeding: It is unknown whether tirzepatide passes into breast milk. Use is not recommended.
- Personal or family history of medullary thyroid carcinoma (MTC): Animal studies showed thyroid C-cell tumours with GLP-1 receptor agonists; causal relevance in humans is uncertain but a personal or family history of MTC is a contraindication.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2): Contraindicated due to the thyroid cancer link above.
- History of pancreatitis: Tirzepatide carries a risk of pancreatitis; prior pancreatitis is a contraindication.
- Concurrent use of another GLP-1 or GIP receptor agonist: Combining tirzepatide with semaglutide, liraglutide, or similar agents is not appropriate.
- Known hypersensitivity to tirzepatide or any excipient.
Questions about Mounjaro eligibility or side effects?
Our GMC-registered GPs can assess your suitability and answer clinical questions. Access Doctor is a GPhC-registered online pharmacy (no. 9011198) — all consultations are conducted by qualified prescribers.
View weight loss treatmentsFrequently asked questions
Will I definitely experience nausea on Mounjaro?
Not necessarily. Nausea is very common but not universal. Its severity varies considerably between individuals. The risk is highest during the first few weeks and at each dose escalation step. Patients who follow dietary guidance — eating smaller meals, avoiding high-fat foods, and staying hydrated — typically experience significantly less nausea than those who do not modify their eating habits.
Can I take anti-nausea medication with Mounjaro?
Some patients find over-the-counter remedies such as ginger-based products helpful for mild nausea. For more persistent or severe nausea, your prescriber may be able to recommend an appropriate anti-emetic. Do not take prescription anti-emetics without first discussing this with your prescriber or pharmacist to check for interactions.
Is it safe to slow down the dose escalation if I have side effects?
Yes. Remaining at a lower dose for an extra 4 weeks before escalating is a recognised and safe approach. The standard schedule is a minimum of 4 weeks at each dose, but there is no maximum. Slowing escalation does not compromise long-term efficacy — you will still reach the therapeutic maintenance dose; it simply takes longer. Discuss this with your prescriber before making any changes.
Can Mounjaro cause low blood sugar?
In patients without diabetes taking Mounjaro as a standalone treatment, hypoglycaemia (low blood sugar) is not expected because tirzepatide’s insulin-stimulating effect is glucose-dependent. However, in patients also taking insulin or sulphonylureas, the combination can increase hypoglycaemia risk, and a medication review is warranted. If you experience symptoms of low blood sugar — shakiness, sweating, confusion, rapid heartbeat — seek prompt medical attention.
How long before the side effects go away completely?
For most patients, the worst GI side effects are during the first 8–10 weeks of treatment, particularly around the first dose escalation. By weeks 8–12, tolerability improves considerably for the majority. At maintenance dose (15 mg), most patients report their side effects are mild or absent. A small proportion of patients do experience persistent GI effects; these individuals should discuss their options with their prescriber, including the possibility of remaining at a lower maintenance dose.
Will my hair grow back after telogen effluvium?
Yes, for most patients. Telogen effluvium caused by rapid weight loss is a temporary disruption to the hair cycle, not permanent hair loss. Hair typically begins to regrow 3–6 months after weight loss stabilises. Ensuring adequate protein and micronutrient intake throughout treatment helps minimise severity and supports recovery.
Can I continue Mounjaro if I develop mild nausea?
Yes — mild to moderate nausea that does not prevent you from eating and drinking is generally manageable without stopping treatment. Dietary adjustments (smaller meals, bland foods, avoiding high-fat foods) are usually sufficient. If nausea is severe, persistent, or accompanied by vomiting that prevents adequate fluid intake, contact your prescriber or call NHS 111.
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
- Medicines and Healthcare products Regulatory Agency. Mounjaro 2.5 mg solution for injection: summary of product characteristics. November 2023. www.medicines.org.uk
- National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity (TA1026). London: NICE; 2024. www.nice.org.uk/guidance/ta1026
- NICE Clinical Knowledge Summary. Obesity. cks.nice.org.uk
- Hughes EC, Saleh D. Telogen effluvium. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. www.ncbi.nlm.nih.gov
- NHS. Weight management medicines. www.nhs.uk
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613–626.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Mounjaro is a prescription-only medicine (POM); it must be prescribed by a qualified healthcare professional following an individual clinical assessment. Do not start, stop, or alter any prescribed medication without consulting your prescriber. If you experience any serious side effects described in this article, seek urgent medical attention. Call NHS 111 for non-emergency medical advice or 999 in an emergency.